• 最初にお読みください
  • 研究班と中央保管機関
  • 研究班と中央保管機関
  • 保管薬剤
  • 治療薬の取り寄せ方法
  • 資料集
  • About Us (ENGLISH)

About Us

About Us

Research Program on Emerging and Re-emerging Infectious Diseases 

Development of optimal medical care network for the diagnosis and treatment of tropical and parasitic diseases in Japan

Research Representative Doctor: Professor, Haruhiko Maruyama (National University Corporation University of Miyazaki)

 

As of April 2015, the Japan Agency for Medical Research and Development has been the contractor of the research group.

 

In 1980, this research group was established to create optimal medical care networks for rare imported and domestic parasitic diseases in Japan. The research group has been directly and indirectly involved in the approval and extension of 13 medications for tropical and parasitic/protozoan diseases (Table 1).

 

In Japan, patients with tropical diseases overseas and after returning to their home countries are sometimes noted. Some medications used to treat tropical diseases are not available in Japan because the number of such cases is extremely low to allow pharmaceutical companies to supply them on a commercial basis.

In 1980, the Ministry of Health, Labour and Welfare (MHLW) led the discussion of this problem, and the research group was established to address it.

 

We are supplying domestically unapproved drugs (Table 2) for severe malaria, toxoplasmosis (without HIV infection), and fascioliasis in the clinical research framework. 

Table 1. Medications that were once approved in Japan and handled by the research group.


 General name  Approval month Indications
Thiabendazole* January, 1987 Strongyloidiasis
Sulfadoxine/pyrimethamine* June, 1987 Malaria
Mebendazole March, 1988 Whipworm infection
Praziquantel September,1988 Clonorchiasis, paragonimiasis, metagonimiasis
Pentamidine isethionate March, 1989 Pneumocystis pneumonia
Albendazole January, 1994 Echinococcosis
Mefloquine October, 2001 Malaria (treatment, prophylaxis)
Ivermectin August, 2002 Strongyloidiasis, scabies
Atovaquone/proguanil December, 2012 Malaria (treatment, prophylaxis)
Paromomycin December, 2012 Intestinal entamoebiasis
Metronidazole, intravenous July, 2014 Entamoebiasis, anaerobic infection
Primaquine March, 2016 Malaria (prevent relapse)
Artemether/lumefantrine December, 2016 Malaria (treatment)

*No longer available

Table 2. Medications stored by the research group (February 2023).

Indications General name
Severe malaria Quinine gluconate, intravenous
Toxoplasmosis Sulfadiazine
Toxoplasmosis Pyrimethamine
Toxoplasmosis Folinate*
Fascioliasis Triclabendazole

* Approved in Japan but not approved for toxoplasmosis combined with pyrimethamine.

Website maintained by the MHLW that discloses information on clinical research (jRCT)

Efficacy and safety of injectable quinine in patients (Injectable quinine for malaria)

https://jrct.niph.go.jp/en-latest-detail/jRCTs071180063

 

Efficacy and safety of pyrimethamine/sulfadiazine/folinate combination therapy for the treatment of disseminated toxoplasmosis and toxoplasma encephalitis (Treatment of disseminated toxoplasmosis/toxoplasma encephalitis with pyrimethamine/sulfadiazine)

https://jrct.niph.go.jp/en-latest-detail/jRCTs071180095

 

Efficacy and safety of pyrimethamine/sulfadiazine/folinate combination therapy for the treatment of ocular toxoplasmosis (Treatment of ocular toxoplasmosis with pyrimethamine/sulfadiazine)

https://jrct.niph.go.jp/en-latest-detail/jRCTs071180092

 

Efficacy and safety of pyrimethamine/sulfadiazine/folinate combination therapy for the treatment of fetal toxoplasmosis (Treatment of fetal toxoplasmosis with pyrimethamine/sulfadiazine)

https://jrct.niph.go.jp/en-latest-detail/jRCTs071180094

 

Efficacy and safety of pyrimethamine/sulfadiazine/folinate combination therapy for the treatment of congenital toxoplasmosis (Treatment of congenital toxoplasmosis with pyrimethamine/sulfadiazine)

https://jrct.niph.go.jp/en-latest-detail/jRCTs071180093

 

Efficacy and safety of triclabendazole for the treatment of fasciolosis (Egaten study)

https://jrct.niph.go.jp/en-latest-detail/jRCTs071190020

   【熱帯病治療薬研究班 事務局】

  ※研究参加に関してのお問合せは以下連絡先まで

  ご連絡ください。

  〒889-1692 宮崎県宮崎市清武町木原5200

   宮崎大学医学部感染症学講座寄生虫学分野

   tel :0985-85-0990 fax:0985-84-3887

 

国立国際医療研究センター 代表 03-3202-7181

治療等の臨床的なお問合せは以下連絡先までご連絡ください。

e-mail: info-dcc<a>hosp.ncgm.go.jp

<a>を@に変えてください。

「熱帯病担当者」へお問い合わせください。